SCHEDULE 13G/A Filing for Ionis Pharmaceuticals Inc

This filing is an amendment to a previous filing by The Vanguard Group, Inc. regarding their ownership of Ionis Pharmaceuticals Inc. The amendment, designated as amendment number 14, pertains to the Common Stock of the issuer. The filing indicates that as of March 13, 2026, The Vanguard Group, Inc. has no beneficial ownership of the securities, with 0 shares reported as beneficially owned. This change is attributed to an internal realignment within The Vanguard Group, Inc. effective January 12, 2026, where certain subsidiaries now report beneficial ownership separately. The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.